Precio VISEN Pharmaceuticals (02561.HK)

VISEN Pharmaceuticals operates as a biopharmaceutical company. The company is headquartered in Suzhou, Jiangsu and currently employs 54 full-time employees. The company went IPO on 2025-03-21. The firm's main products under development include lonapegsomatropin, navepegritide, and palopegteriparatide. The lonapegsomatropin is used to treat growth hormone deficiency in children aged 3 to 17 years old. The navepegritide is a disease repair therapy used to treat children with cartilage dysplasia aged 2 to 10 years old. The palopegteriparatide is a treatment method used to treat adult hypoparathyroidism. The firm is in the late stage of research and development, and its products are close to commercialization.